Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan
Samsung Biologics subsidiary Samsung Bioepis signed a licensing and commercialization agreement with Japan's Nipro Corporation to bring several biosimilar candidates, including SB17, a ustekinumab biosimilar, to Japan. Under the agreement, Samsung Bioepis will oversee development, manufacturing, and supply, while NIPRO will handle commercialization in Japan, Samsung Bioepis said in a Monday press release. The partnership aims to expand Samsung Bioepis' presence in Japan and improve access to cost-effective biologic treatments, it said.
Trading View·